<DOC>
	<DOCNO>NCT01432353</DOCNO>
	<brief_summary>This multicenter , open-label , dose-escalating study ass safety efficacy DFRF4539A patient relapse refractory multiple myeloma . Cohorts patient receive multiple ascend dos intravenous DFRF4539A every 3 week weekly . Patients exhibit acceptable safety evidence clinical benefit may receive DFRF4539A 17 cycle . Anticipated time study treatment 1 year disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study DFRF4539A Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Adult patient ; &gt; /= 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Relapsed refractory multiple myeloma effective standard therapy exist One prior therapy must include proteosome inhibitor immunomodulatory drug Measurable disease define protocol Prior use monoclonal antibody within 4 week Cycle 1 , Day 1 Treatment radiotherapy , thalidomide , lenalidomide , bortezomib , chemotherapeutic agent , treatment investigational anticancer agent within 2 week prior Cycle 1 , Day 1 Toxicities previous treatment must resolve prior Cycle 1 , Day 1 , except neuropathy Completion autologous stem cell transplant within 100 day prior Cycle 1 , Day 1 Prior allogeneic stem cell transplant History severe allergic anaphylactic reaction monoclonal antibody therapy ( recombinant antibodyrelated fusion protein ) Grade &gt; 1 peripheral neuropathy Active infection screen major episode infection require treatment IV antibiotic hospitalization within 4 week prior Cycle 1 , Day 1 Positive hepatitis B , hepatitis C HIV infection Pregnant lactate woman woman intend become pregnant within period time study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>